XBiotech Inc
Suletud
2.25 -1.32
Ülevaade
Aktsiahinna muutus
24h
Min
2.21
Max
2.2800000000000002
Sissetulek | -1.2M -6.7M |
|---|---|
Aktsiakasum | -0.22 |
Töötajad | 87 |
EBITDA | 399K -4.7M |
Järgmine tulemuste avaldamine | 10. nov 2026 |
|---|
Turukapital | 915K 70M |
|---|---|
Eelmine avamishind | 3.57 |
Eelmine sulgemishind | 2.25 |
XBiotech Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
XBiotech Inc Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.